Literature DB >> 22706581

A fluorescent screening assay for identifying modulators of GIRK channels.

Maribel Vazquez1, Charity A Dunn, Kenneth B Walsh.   

Abstract

G protein-gated inward rectifier K+ (GIRK) channels function as cellular mediators of a wide range of hormones and neurotransmitters and are expressed in the brain, heart, skeletal muscle and endocrine tissue(1,2). GIRK channels become activated following the binding of ligands (neurotransmitters, hormones, drugs, etc.) to their plasma membrane-bound, G protein-coupled receptors (GPCRs). This binding causes the stimulation of G proteins (Gi and Go) which subsequently bind to and activate the GIRK channel. Once opened the GIRK channel allows the movement of K+ out of the cell causing the resting membrane potential to become more negative. As a consequence, GIRK channel activation in neurons decreases spontaneous action potential formation and inhibits the release of excitatory neurotransmitters. In the heart, activation of the GIRK channel inhibits pacemaker activity thereby slowing the heart rate. GIRK channels represent novel targets for the development of new therapeutic agents for the treatment neuropathic pain, drug addiction, cardiac arrhythmias and other disorders(3). However, the pharmacology of these channels remains largely unexplored. Although a number of drugs including anti-arrhythmic agents, antipsychotic drugs and antidepressants block the GIRK channel, this inhibition is not selective and occurs at relatively high drug concentrations(3). Here, we describe a real-time screening assay for identifying new modulators of GIRK channels. In this assay, neuronal AtT20 cells, expressing GIRK channels, are loaded with membrane potential-sensitive fluorescent dyes such as bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)] or HLB 021-152 (Figure 1). The dye molecules become strongly fluorescent following uptake into the cells (Figure 1). Treatment of the cells with GPCR ligands stimulates the GIRK channels to open. The resulting K+ efflux out of the cell causes the membrane potential to become more negative and the fluorescent signal to decrease (Figure 1). Thus, drugs that modulate K+ efflux through the GIRK channel can be assayed using a fluorescent plate reader. Unlike other ion channel screening assays, such atomic absorption spectrometry(4) or radiotracer analysis(5), the GIRK channel fluorescent assay provides a fast, real-time and inexpensive screening procedure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706581      PMCID: PMC3466633          DOI: 10.3791/3850

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays.

Authors:  Christian Wolff; Bruno Fuks; Pierre Chatelain
Journal:  J Biomol Screen       Date:  2003-10

3.  Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.

Authors:  Terry R Bridal; Michael Margulis; Xin Wang; Michael Donio; Steve Sorota
Journal:  Assay Drug Dev Technol       Date:  2010-07-26       Impact factor: 1.738

Review 4.  G protein-activated inwardly rectifying potassium channels as potential therapeutic targets.

Authors:  Toru Kobayashi; Kazutaka Ikeda
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors.

Authors:  Colleen M Niswender; Kari A Johnson; Qingwei Luo; Jennifer E Ayala; Caroline Kim; P Jeffrey Conn; C David Weaver
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

Review 6.  Inwardly rectifying potassium channels: their structure, function, and physiological roles.

Authors:  Hiroshi Hibino; Atsushi Inanobe; Kazuharu Furutani; Shingo Murakami; Ian Findlay; Yoshihisa Kurachi
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

7.  Development and evaluation of high throughput functional assay methods for HERG potassium channel.

Authors:  W Tang; J Kang; X Wu; D Rampe; L Wang; H Shen; Z Li; D Dunnington; T Garyantes
Journal:  J Biomol Screen       Date:  2001-10

8.  A high-throughput HERG potassium channel function assay: an old assay with a new look.

Authors:  Charles S Cheng; Dawn Alderman; Jennifer Kwash; John Dessaint; Rita Patel; Mary Kay Lescoe; Michele Bennett Kinrade; Weifeng Yu
Journal:  Drug Dev Ind Pharm       Date:  2002       Impact factor: 3.225

9.  Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay.

Authors:  G C Terstappen
Journal:  Anal Biochem       Date:  1999-08-01       Impact factor: 3.365

10.  Antiarrhythmic agents act differently on the activation phase of the ACh-response in guinea-pig atrial myocytes.

Authors:  N Inomata; T Ohno; T Ishihara; N Akaike
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

View more
  3 in total

1.  Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells.

Authors:  Lia Baki; Miguel Fribourg; Jason Younkin; Jose Miguel Eltit; Jose L Moreno; Gyu Park; Zhanna Vysotskaya; Adishesh Narahari; Stuart C Sealfon; Javier Gonzalez-Maeso; Diomedes E Logothetis
Journal:  Pflugers Arch       Date:  2016-01-16       Impact factor: 3.657

2.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

3.  Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Authors:  Thomas Günther; Michael Culler; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.